HK1244821A1 - 用於治療和診斷1型糖尿病中使用的肽 - Google Patents

用於治療和診斷1型糖尿病中使用的肽

Info

Publication number
HK1244821A1
HK1244821A1 HK18104063.4A HK18104063A HK1244821A1 HK 1244821 A1 HK1244821 A1 HK 1244821A1 HK 18104063 A HK18104063 A HK 18104063A HK 1244821 A1 HK1244821 A1 HK 1244821A1
Authority
HK
Hong Kong
Prior art keywords
diabetes
peptides
diagnosis
treatment
type
Prior art date
Application number
HK18104063.4A
Other languages
English (en)
Inventor
Robert P Anderson
Original Assignee
Immusant Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusant Inc filed Critical Immusant Inc
Publication of HK1244821A1 publication Critical patent/HK1244821A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
HK18104063.4A 2014-11-21 2018-03-23 用於治療和診斷1型糖尿病中使用的肽 HK1244821A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082823P 2014-11-21 2014-11-21
PCT/US2015/061931 WO2016081869A2 (en) 2014-11-21 2015-11-20 Peptides for use in treatment and diagnosis of type 1 diabetes

Publications (1)

Publication Number Publication Date
HK1244821A1 true HK1244821A1 (zh) 2018-08-17

Family

ID=55024215

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18104063.4A HK1244821A1 (zh) 2014-11-21 2018-03-23 用於治療和診斷1型糖尿病中使用的肽

Country Status (7)

Country Link
US (2) US10473647B1 (zh)
EP (1) EP3221344A2 (zh)
CN (1) CN107531767A (zh)
AU (1) AU2015349728A1 (zh)
CA (1) CA2968422A1 (zh)
HK (1) HK1244821A1 (zh)
WO (1) WO2016081869A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019104391A1 (en) * 2017-12-01 2019-06-06 St Vincent's Institute Of Medical Research Type 1 diabetes treatment
EP4010353A4 (en) * 2019-08-05 2023-08-23 Icahn School of Medicine at Mount Sinai PEPTIDES THAT BLOCK THE PRESENTATION OF ANTIGEN ISLAND PEPTIDES BY HLA-DQ8 AND METHODS OF TREATING TYPE 1 DIABETES

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840836A (en) * 1989-02-17 1998-11-24 Bayer Corporation Pancreatic islet cell antigens obtained by molecular cloning
US5674978A (en) 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
US5998366A (en) 1990-09-21 1999-12-07 The Regents Of The University Of California Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders
EP0852004B1 (en) 1995-10-11 2011-01-19 Luminex Corporation Multiplexed analysis of clinical specimens
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
US5939281A (en) 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
FR2764989B1 (fr) 1997-06-20 1999-08-27 Pasteur Sanofi Diagnostics Procede de dosage du c-peptide
IL135593A (en) 1997-10-14 2004-06-01 Luminex Corp Precisely fluorescently painted polymeric microspheres and methods for making and using them
AUPP320998A0 (en) * 1998-04-27 1998-05-21 Walter And Eliza Hall Institute Of Medical Research, The Tyrosine phosphatase IA-2 T-cell epitopes
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
US20030166589A1 (en) 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis
US8148171B2 (en) 2001-10-09 2012-04-03 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
US20050053954A1 (en) 2002-11-01 2005-03-10 Brennan John D. Multicomponent protein microarrays
GB0402129D0 (en) 2004-01-30 2004-03-03 King S College London Therapeutic and diagnostic peptides
WO2005105129A2 (en) 2004-04-28 2005-11-10 Btg International Limited Epitopes related to coeliac disease
WO2006007667A1 (en) 2004-07-23 2006-01-26 The Walter And Eliza Hall Institute Of Medical Research Therapeutic and diagnostic agents
JP5042859B2 (ja) 2005-01-20 2012-10-03 ルミネックス コーポレーション 蛍光ベースの応用で使用される磁性ミクロスフェア
CN102621053B (zh) 2005-09-21 2015-05-06 卢米尼克斯股份有限公司 图像数据处理的方法和系统
US8378072B2 (en) 2006-04-13 2013-02-19 Declion Pharmaceuticals, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
US8296088B2 (en) 2006-06-02 2012-10-23 Luminex Corporation Systems and methods for performing measurements of one or more materials
IN2015DN03125A (zh) 2006-09-05 2015-10-02 Hvidovre Hospital
US20120214963A1 (en) 2011-02-23 2012-08-23 Elona Biotechnologies Aspart proinsulin compositions and methods of producing aspart insulin analogs therefrom
WO2008100791A1 (en) 2007-02-16 2008-08-21 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of sickle cell
GB0712670D0 (en) * 2007-06-29 2007-08-08 King S College London Isolated peptides and uses thereof
EP2977053B1 (en) 2008-11-30 2017-07-05 Immusant, Inc. Compositions and methods for treatment of celiac disease
AU2009335712B2 (en) 2008-12-19 2015-09-17 Indiana University Research And Technology Corporation Insulin analogs
US8274656B2 (en) 2010-06-30 2012-09-25 Luminex Corporation Apparatus, system, and method for increasing measurement accuracy in a particle imaging device
WO2012007950A2 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
CN103619880A (zh) 2011-04-29 2014-03-05 百时美施贵宝公司 Ip-10抗体剂量递增方法
US20140342936A1 (en) 2011-12-15 2014-11-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and kits for diagnosing latent tuberculosis infection
CA2906044A1 (en) 2013-03-14 2014-09-25 Immusant, Inc. Placebo-controlled gluten challenge method
WO2015038624A1 (en) 2013-09-10 2015-03-19 Immusant, Inc. Dosage of a gluten peptide composition
EP3046576A4 (en) 2013-09-20 2017-07-12 Immusant Inc. Compositions and methods related to oat sensitivity
EP3134425A4 (en) 2014-04-24 2018-06-20 Immusant Inc. Compositions comprising gluten peptides and uses thereof
US20170059582A1 (en) 2014-04-24 2017-03-02 Immusant, Inc. Methods for diagnosing celiac disease using circulating cytokines/chemokines
US20170097346A1 (en) 2014-04-24 2017-04-06 Immusant, Inc. Use of interleukin-2 for diagnosis of celiac disease
AU2015323979A1 (en) 2014-09-29 2017-05-18 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease

Also Published As

Publication number Publication date
CN107531767A (zh) 2018-01-02
CA2968422A1 (en) 2016-05-26
WO2016081869A2 (en) 2016-05-26
US20200141924A1 (en) 2020-05-07
EP3221344A2 (en) 2017-09-27
AU2015349728A1 (en) 2017-07-13
WO2016081869A3 (en) 2016-07-14
US10473647B1 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
IL256687B (en) Isolated tau-binding antibody and its use in treatment and diagnosis
HRP20180631T1 (hr) Analog mini-gastrina, posebno u uporabi za dijagnozu i/ili liječenje tumora pozitivnog na receptor cck2
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
LT3197472T (lt) Rekombinantinių baltymų be fenilalanino naudojimas gydant fenilketonuriją
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
ZA201704726B (en) Peptides and their use in the treatment of skin
SG11201703704PA (en) Diagnosis and treatment of incipient diabetes
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
ZA201905851B (en) Peptides and methods for the treatment of diabetes
GB201413357D0 (en) Antibodies for treatment and diagnosis
EP3123176A4 (en) Diagnosis of multiple sclerosis in human and animal subjects
PT3177599T (pt) Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória
HK1244821A1 (zh) 用於治療和診斷1型糖尿病中使用的肽
PL3234597T3 (pl) Białka szlaku sygnałowego wnt i ich zastosowanie w diagnostyce i leczeniu zaburzeń hipopigmentacji
PT3129398T (pt) Novos agentes médicos e usos dos mesmos
GB201500875D0 (en) Antibodies for treatment and diagnosis
DK3366306T3 (en) Use of some peptides in diagnosis and treatment of diabetes, obesity and metabolic diseases associated thereto
IL250666B (en) A peptide for the treatment of diabetes mellitus type 2 and its complications
IL252043A0 (en) A proline-rich polypeptide complex for use in the treatment of brain neurotrophic factor-related disorders
GB201513543D0 (en) Compositions for use in the treatment of diabetes
PL3139948T3 (pl) Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21
GB201418541D0 (en) Materials for use with general hyperthermia treatment
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
IL247732A0 (en) Perinase inhibitory peptides and their use in the treatment of clinical pathologies
ZA201404780B (en) Composition for use in treatment of diabetes